Abstract
The serotonin receptor subtype 5-HT1A was one of the first serotonin receptor subtypes pharmacologically characterized. Over the last twenty years the 5-HT1A receptor has been the object of intense research efforts as witnessed by the 5-HT1A acting drugs marketed as anxiolytics. In recent years, several new chemical entities targeting the 5-HT1A receptor (alone or in combination with other molecular targets) have been proposed for novel therapeutic indications (neuroprotection, cognitive impairment, Parkinson Disease and related disorders, pain treatment). The present review will focus on those 5-HT1A receptor agents that entered preclinical trials starting from 2000.
Keywords: serotonin receptor, anxiolytics, neuroprotection, cognitive impairment, Parkinson Disease, Therapeutic Agents
Current Topics in Medicinal Chemistry
Title: 5-HT1A Receptor, an Old Target for New Therapeutic Agents
Volume: 8 Issue: 12
Author(s): Enza Lacivita, Marcello Leopoldo, Francesco Berardi and Roberto Perrone
Affiliation:
Keywords: serotonin receptor, anxiolytics, neuroprotection, cognitive impairment, Parkinson Disease, Therapeutic Agents
Abstract: The serotonin receptor subtype 5-HT1A was one of the first serotonin receptor subtypes pharmacologically characterized. Over the last twenty years the 5-HT1A receptor has been the object of intense research efforts as witnessed by the 5-HT1A acting drugs marketed as anxiolytics. In recent years, several new chemical entities targeting the 5-HT1A receptor (alone or in combination with other molecular targets) have been proposed for novel therapeutic indications (neuroprotection, cognitive impairment, Parkinson Disease and related disorders, pain treatment). The present review will focus on those 5-HT1A receptor agents that entered preclinical trials starting from 2000.
Export Options
About this article
Cite this article as:
Lacivita Enza, Leopoldo Marcello, Berardi Francesco and Perrone Roberto, 5-HT1A Receptor, an Old Target for New Therapeutic Agents, Current Topics in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/156802608785161385
DOI https://dx.doi.org/10.2174/156802608785161385 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Caspase Function in Neuronal Death: Delineation of the Role of Caspases in Ischemia
Current Drug Targets - CNS & Neurological Disorders Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Current Neuropharmacology Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Is the Multifunctional Na+/H+ Exchanger Isoform 1 a Potential Therapeutic Target in Cancer?
Current Medicinal Chemistry Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Cardiolipin Metabolism and the Role it Plays in Heart Failure and Mitochondrial Supercomplex Formation
Cardiovascular & Hematological Disorders-Drug Targets Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry Nanoparticulated Nitric Oxide Donors and their Biomedical Applications
Mini-Reviews in Medicinal Chemistry Therapeutic Strategies in Allergic Contact Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Inhibitors of c-jun-N-Terminal Kinase (JNK)
Mini-Reviews in Medicinal Chemistry Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets Brain Perfusion In Sepsis
Current Vascular Pharmacology Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications
Current Medicinal Chemistry Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology